Incubation of bovine aortic endothelial cells (BAECs)
with erythrocytes from patients with type 2 diabetes induced an increase in endothelin 1 (ET-1) production. The effect of erythrocytes on ET-1 synthesis was dependent on glycemic control. ET-1 levels after incubation with erythrocytes derived from patients with HbA 1c levels <6% were just half the levels observed after incubation with erythrocytes from patients with HbA 1c levels >8%. N -(carboxymethyl)lysine (CML)-containing protein isolated from patients' erythrocytes induced ET-1, and CML-containing protein-dependent ET-1 induction was blocked by the recombinant decoy peptide soluble receptor for advanced glycation end products (AGEs), which comprises the NH 2 E ndothelin 1 (ET-1), a 21-amino acid peptide, is known to be one of the most potent vasoconstrictors and to be a mitogen (1, 2) . ET-1 mRNA is constitutively expressed in cultured endothelial cells (ECs). The release of ET-1 from ECs can be stimulated by several factors such as interleukin-1, tumor necrosis factor-␣, thrombin, angiotensin II, and oxygen radicals (3) (4) (5) (6) (7) . ET-1 is first transcribed as the precursor molecules prepro-ET-1 and pro-ET-1 and is later processed to the biologically active ET-1 by the endothelin-converting enzyme (8) . A significant increase in circulating ET-1 in patients with advanced atherosclerosis has been reported (9) . Recent studies have shown not only an increased local ET-1 concentration (10) but also increased ET-1 mRNA in arteries containing atherosclerotic lesions (11) .
Risk factors for the development of atherosclerosis, such as diabetes, also seem to be associated with elevated plasma ET-1 levels (12) . Late complications in patients with diabetes such as nephropathy, neuropathy, and retinopathy are associated with at least 2 pathophysiological conditions: 1) enhanced development and accumulation of advanced glycation end products (AGEs) and 2) an increased formation of intracellular oxidative stress (13, 14) .
Proteins exposed to glucose become nonenzymatically glycated, resulting in the formation of Amadori products. The best known Amadori product is HbA 1c , which is used for monitoring glucose metabolism in patients with diabetes. Longer-lasting exposure leads to formation of irreversibly glycated proteins. These AGEs are formed and accumulate in the vessel wall during normal aging. Their formation and accumulation increase in patients with long-lasting hyperglycemia as occurs in diabetes (15) . Accumulation of AGEs in the vessel wall and different organs seems to be linked to the development of microvascular and macrovascular disease and other secondary complications of diabetes. Administration of AGE albumin to healthy nondiabetic animals was followed by vascular dysfunction similar to that associated with experimental diabetes (16) . This cellular response is thought to be mediated through the binding of AGEs to a specific cell-surface receptor (the receptor for advanced glycation end products [RAGE]) (17) . Inhibition of AGE-RAGE interaction affects hyperpermeability (18) and macrovascular arteriosclerosis (19) . Ligand receptor interaction results in the generation of intracellular oxidative stress and activation of the redox-sensitive transcription factor nuclear factor-B (NF-B) (20, 21) . Patients with poor glycemic control and diabetic nephropathy have been shown to have elevated levels of AGEs (22, 23) , oxidative stress (24) , mononuclear NF-B binding activity (25) , and elevated levels of ET-1 (9, 11, 12) . Therefore, we asked whether AGE-RAGE-dependent NF-B activation could contribute to ET-1 induction.
RESEARCH DESIGN AND METHODS
Reagents. Reagents were obtained as follows: DMEM, RPMI-1640, HEPES buffer solution, L-glutamine, penicillin/streptomycin mixture, and phosphatebuffered saline (pH 7.4) were from Biowhittaker (Walkerville). Fetal calf serum (FCS) was from Boehringer Mannheim (Mannheim, Germany).
[␣-
32 P]dCTP (3,000 Ci/mmol at 10 Ci/ml), [␣-32 P]UTP (3,000 Ci/mmol at 10 Ci/ml), [␥-
32 P]ATP (3,000 Ci/mmol at 10 Ci/ml), and Hybond-N nylon filter were obtained from Amersham (Braunschweig, Germany). Ficoll-Paque was from Pharmacia (Uppsala, Sweden). Benzamidine, leupeptin, phenylmethylsulfonyl fluoride (PMSF), pyrrolidine-dithiocarbamate (pDTC), and soybean inhibitor were obtained from Sigma (St. Louis, MO). Isolation and Western blot of N -(carboxymethyl)lysine-modified proteins. Erythrocytes were lysed in 0.9% NaCl, 1.5 mmol/l PMSF, 0.1 mmol/l leupeptin, 20 mg/ml soybean inhibitor, and 2 mmol/l benzamidine by 3 freeze/thaw cycles followed by pulsed ultrasonication for 3 min and a final freeze/thaw cycle. Insoluble material was removed by 5 min of centrifugation at 6,000 rpm at 4°C, and the supernatant was used for N -(carboxymethyl)lysine (CML) extraction.
Isolation of CML-modified proteins from erythrocyte lysates was performed as follows. CML-modified proteins, anti-CML-coupled sepharose, and an unrelated control antibody-coupled sepharose were prepared as previously described in detail (26) . A total of 10 µg total erythrocyte lysate from 1 patient (HbA 1c 14.3%) was loaded onto a 1-ml anti-CML-sepharose column or a 1-ml anti-phosphatidylinositol 4-phosphate (PIP) kinase-coupled sepharose column and was incubated for 2 h at room temperature while shaken continuously. After extensive washing with 7 ϫ 10 ml 0.9% NaCl, CML-modified proteins were eluted with 1 mol/l glycine (pH 3.0), were neutralized, and were dialyzed before protein concentration was determined using the bicinchoninic acid assay system (Pierce, Rockford, IL).
Furthermore, 50 µg total erythrocyte lysate or 5 µg material eluted from CML-sepharose columns or control antibody-sepharose columns was loaded onto 10% SDS-PAGE followed by electroblotting to enhanced chemiluminescence (ECL)-nitrocellulose membranes. Blocking was performed overnight at 4°C in 0.2% casein (I-Block; Tropix, Bedford, MA) dissolved in Tris-buffered saline (TBS) supplemented with 0.1% Tween (TBST). Membranes were incubated for 45 min at room temperature with a primary antibody for CML diluted 1:8,000 in blocking solution. Membranes were washed for 2 ϫ 15 min in TBST before the secondary antibody (horseradish peroxidase-coupled rabbit IgG, 1:3,000) was added, and incubation continued for 30 min at room temperature. Membranes were washed 3 ϫ 15 min as above followed by detection of immunoreactive proteins using the ECL Western blot system (Amersham, Braunschweig, Germany) from 10 s to 1 min. Preparation of soluble RAGE. The first Ig domain (residues 21-132) of the human RAGE receptor was cloned into a modified pET9D expression vector (Novagen, Madison, WI) and was overexpressed in Escherichia coli. The sequence was confirmed by DNA sequencing. The 111-residue recombinant protein was purified by affinity chromatography on an Ni-chelating sepharose fast flow column (Pharmacia, Freiburg, Germany) followed by gel filtration. Based on 1-and 2-dimensional nuclear magnetic resonance experiments, the recombinant Ig domain adopts a tertiary structure and is folded. Competition with a 3-fold molar excess of the recombinant Ig domain results in reduced cellular activation mediated by ligand binding to RAGE. Preparation of AGE albumin. AGE albumin was prepared by preincubation of bovine serum albumin (BSA) with 200 mmol/l glucose at 37°C for 4-8 weeks in 100 mmol/l phosphate (pH 7.4) and 0.5 mmol/l sodium azide. At the end of incubation, AGE albumin was dialyzed against 100 mmol/l phosphate for 24 h and 0.9% NaCl for 12 h. Nonglycated BSA, heat-inactivated AGE, and BSA incubated with the synthetic substrate sorbitol served as negative controls. AGE albumin preparations were characterized by chromatographic means (27) . Fructoselysine, pyrraline, and unmodified lysine were quantified after enzymatic hydrolysis via ion-exchange chromatography with direct ultraviolet detection and subsequent ninhydrin derivatization. Quantification of pentosidine was obtained in acid hydrolysates using ion-exchange chromatography with direct fluorescence detection. Carboxymethyl lysine and other amino acids were quantified on the amino acid analyzer after acid hydrolysis. Lysine modifications of the used AGE preparations varied from 10 to 36%. Assays for endotoxin showed that AGE albumin preparations contained virtually undetectable levels of lipopolysaccharide (<10 pg/ml at a protein concentration of 5 mg/ml). Plasmids. The simian virus (SV) 40-driven luciferase control plasmid pGl2-control, the promoterless plasmid pGl2-basic, the ␤-galactosidase control plasmid pSV-␤-Gal, and the chloramphenicol transferase control vector pCATcontrol were obtained from Promega (Madison, WI). NF-B p50, NF-B p65, and the cytoplasmic inhibitor of NF-B (I-B␣) were provided by Dr. P.A. Baeuerle (Tularik, San Francisco, CA). Human ET-1 cDNA was a gift from Dr. T. Yanagisawa (Kyoto, Japan). For functional promoter studies, the 3,604-bp long 5Ј flanking region of the human ET-1 gene was inserted into the multiple cloning site of the plasmid pGl2-basic after digestion with KpnI and BglII (pET[-3,604]Luc). The plasmid pET [-490 ]Luc, which lacks the potential NF-B binding site, was generated through digestion of pET [-3,604 ]Luc with Exonuclease III (Promega). All plasmids were verified by sequencing using GLprimer 1 and Glprimer 2 from Promega. Tissue culture. Bovine aortic endothelial cells (BAECs) were cultured in DMEM supplemented with 10% FCS as previously described (28) , and primary cultures were established according to Jaffe et al. (29) . Cells were identified as ECs by positive immunofluorescence staining for von Willebrand factor antigen and according to typical morphological features. BAECs were passaged every 8-10 days without showing morphological changes. All experiments were performed with BAECs at passages 4-6, which had been confluent for 3 days. For transfection experiments, BAECs growing in the logarithmic phase were used. Measurement of HbA 1c and isolation of erythrocytes. HbA 1c levels of venous blood samples anticoagulated with EDTA (Becton Dickinson Vacutainer system; Meylan Cedex, France) from 55 patients with type 2 diabetes were assayed by a routinely used high-performance liquid chromatography (HPLC) method based on the procedure described by Bisse and Wieland (30) on a Shimadzu HPLC system (Kyoto, Japan). The nondiabetic reference range for HbA 1c is 4-6%. A total of 21 patients had HbA 1c levels between 6.0 and 7.9%, and 29 patients had HbA 1c levels >8.0%. The patients did not receive therapy other than antidiabetic drugs. The control group consisted of 10 healthy nondiabetic volunteers. Written consent was obtained from all participants after explaining the nature of the procedure.
EDTA-anticoagulated blood was centrifuged to remove plasma and buffy coat, and packed erythrocytes were washed 2 times before incubating 4 ϫ 10
5
BAECs with 4 ϫ 10 9 erythrocytes for 24 h (18,21,31). Determination of ET-1. ET-1 was prepurified from tissue culture supernatants by methanol extraction from Sep-Pak Plus C 18 cartridges (Millipore, Milford, MA). The eluted samples were then applied to a radioimmunoassay based on rabbit anti-ET-1 serum and a 125 I-ET-1 tracer (Biomedica, Vienna, Austria). Radioimmunoassay was performed according to the manufacturer's instructions. The assay showed an intra-assay coefficient of variation <3% and an interassay coefficient of variation of 12%. RNA isolation and Northern blot hybridization. After induction, cells were pelleted, and total RNA was prepared as described by Chirgwin et al. (32) . For Northern blot analysis, RNA samples of 20 µg each were size fractionated by 1.2% formaldehyde agarose gel electrophoresis and were transferred to Hybond-N membranes (Amersham, Braunschweig, Germany). The filters were baked at 80°C for 2 h, were prehybridized for 2 h, and were then hybridized for 12-16 h at 65°C in 50 mmol/l PIPES buffer (pH 6.8), 200 mmol/l NaCl, 20 mmol/l Na 2 HPO 4 , 30 mmol/l NaH 2 PO 4 , 1 mmol/l EDTA, 5% SDS, and 100 µg/ml sonicated salmon sperm DNA. A 480-bp SacI insert of the ET-1 cDNA was labeled with [␣-32 P]dCTP by the random prime technique (33) and was used as an ET-1-specific probe. The blots were washed 3 times with prewarmed 1.3 ϫ sodium chloride-sodium citrate (SSC) and 5% SDS at 65°C. Filters were exposed for 2 days at -70°C to Kodak XAR-5 films (Rochester, NY) using intensifying screens. Reverse transcriptase-polymerase chain reaction. For reverse transcriptase-polymerase chain reaction (RT-PCR), total RNA was prepared using the RNeasy Kit (Qiagen, Hilden, Germany) according to the manufacturer's instructions. RT-PCR for ET-1 followed the protocol of Ehrenreich (34) with minor modifications. cDNA was reverse transcribed from 1 µg of total RNA with oligo-dT primers (Pharmacia, Freiburg, Germany) and avian myeloblastosis virus (AMV)-reverse transcriptase (Promega, Heidelberg, Germany). Amplification was performed using the primer pairs ET-1 forward primer 5Ј-GTCAACACTCCCGAGCACG-3Ј, ET-1 reverse primer 5Ј-CTGGTTTGTCTTA GGTGTTCC-3Ј, actin forward primer 5Ј-AGAGGTATCCTGACCCTGAAGTA Nuclear run-on assay. Nuclear run-on assays were performed according to the procedure of Greenberg and Ziff (35) . Briefly, after incubation with AGEs, or 42 h after transfection, nuclei were harvested from 2 ϫ 10 7 cells. Run-on reactions were performed in 0.7 mol/l KCl, 50 mmol/l MgCl 2 , 50 mmol/l Tris-HCl (pH 8.0), 25 mmol/l diothreitol (DTT), and 1 mmol/l EDTA in the presence of 250 µCi [␣-32 P]UTP (3,000 Ci/mmol) and were incubated for 30 min at 30°C. The synthesized mRNA was incubated with DNAse I for 5 min at 30°C, was treated with proteinase K (10 mg/ml), and was extracted with 0.45 µm millipore filters HA. RNA was collected by ethanol precipitation and was redissolved in 300 µl diethyl pyrocarbonate-H 2 O; 1 µl was counted, and equal numbers of Cerenkov counts were made up to 2 ml hybridization solution and were added to the previously prepared dot blot filters. Hybridization was performed without prehybridization in 50% formamide, 5 ϫ SSC, 5 ϫ Denhardt solution, and 1% SDS for 4 days at 42°C. Filters were washed 3 times at room temperature for 10 min in 2 ϫ SSC and once at 60°C in 1 ϫ SSC. Filters were exposed to Kodak XAR-5 films for 1-4 weeks at -70°C with intensifying screens. For preparation of filters, 3 µg human ET-1 DNA or the respective control plasmids (glyceraldehyde-3-phosphate dehydrogenase [GAPDH]) were applied to Hybond-N membranes using a dot blot apparatus (Schleicher & Schuell, Dassel, Germany). Application of phosphorothioate oligonucleotides. The sequence of the used bovine RAGE antisense oligonucleotide is 5Ј-GACCACTGCCCCTG CTGC-3Ј, and the sequence of the human RAGE antisense oligonucleotide is 5Ј-AACTGCTGTTCCGGCTGC-3Ј. They comprise the region from +13 bp to +30 bp of the bovine and from +4 bp to +21 bp of the human published DNA sequence for RAGE (36) . The used RAGE sense oligonucleotide sequences are complementary to the described sequences. They were synthesized on a Gene Assembler Plus (Pharmacia, Freiburg, Germany) and were purified on histidine gels (37) . To protect oligonucleotides against nuclease-mediated degradation, they were synthesized as phosphorothioate derivates. Oligonucleotides were added to cell culture medium at a concentration of 0.1 µmol/l and were applied 48 h before incubation with 500 nmol/l AGEs. Stability, internalization, and successful downregulation of RAGE mRNA synthesis through antisense oligonucleotides were monitored by RT-PCR as described previously (38) . Transient transfection of BAECs. Logarithmically growing ECs were transfected as described by Lee et al. (39) with minor modifications (40) . Plasmid DNA used in transfection was isolated by CsCl equilibrium centrifugation (41) . Cells growing in DMEM containing 10% FCS were transfected by the calcium phosphate method and were exposed to the precipitate for 8 h. The medium was changed, and cells were incubated for 42 h and then harvested in the appropriate buffers. Cell extracts were prepared by lysis in 25 mmol/l Tris-phosphate (pH 7.8), 2 mmol/l DTT, 2 mmol/l 1,2-diaminocyclohexane-N,N,N,N-tetraacetic acid, 10% glycerol, and 1% Triton X-100 and were assayed directly for luciferase activity and ␤-galactosidase activity as previously described (40) . The ratio of luciferase activity to ␤-galactosidase activity served to normalize the luciferase activity. Each experiment was performed in triplicate at least 3 times. Electrophoretic mobility shift assay. For electrophoretic mobility shift assays (EMSAs), nuclear proteins were harvested as previously described (40) and were assayed for NF-B binding activity using the following oligonucleotides: the NF-B consensus sequence 5Ј-AGTTGAGGGGACTTTCCCA GGC-3Ј and the ET-1-derived NF-B sequence 5Ј-AAGTAGGGGGAGTCCCTG CCAAGAC-3Ј. The oligonucleotides were end labeled with polynucleotide kinase in the presence of [␥- 32 P]ATP to a specific activity >5 ϫ 10 7 cpm/µg DNA. Specificity of binding was ascertained by competition with a 160-fold molar excess of unlabeled consensus oligonucleotides. Data analysis. Data are means (ranges). Because of nonnormal distribution, nonparametric tests were used. For comparisons between the groups, the Kruskal-Wallis analysis of variance and the Mann-Whitney U test were applied. Spearman's rank correlation test was used to calculate correlations.
RESULTS
Erythrocytes isolated from patients with type 2 diabetes are able to induce ET-1 in cultured ECs. The 4 ϫ 10 5 BAECs were incubated with 4 ϫ 10 9 isolated erythrocytes from patients with type 2 diabetes (n = 55) and from 10 healthy control subjects to study whether hyperglycemiadependent modification of erythrocyte membrane proteins affects ET-1 production of ECs. The ET-1 content of the supernatant was determined by a radioimmunoassay 24 h after the addition of erythrocytes. In this experimental setting, an increase in ET-1 was observed that correlated with the HbA 1c levels of the patients (r = 0.77) with a maximum increase at HbA 1c levels >8.0% (P < 0.00001, Fig. 1A) . Thus, erythrocytes derived from diabetic patients with poor glycemic control had a stronger ET-1-inducing activity on BAECs than erythrocytes derived from patients with good glycemic control. Hyperglycemia is associated with increased formation of AGEs.
Consistently, Western blot analysis performed with antibodies directed against CML demonstrated that total erythrocyte lysates from hyperglycemic patients (HbA 1c 14.3%) contained more CML-reactive material than erythrocyte lysates derived from subjects with good glycemic control (Fig. 1B) . Two prominent bands were detected. The upper band of an apparent molecular weight of 70 kD was found only in the erythrocytes of patients with bad glycemic control, and a lower band of ~30 kD was present in all extracts tested. When erythrocytes from hyperglycemic patients were enriched for CML-modified proteins using an anti-CML antibody coupled to BrCN-activated sepharose, CML-modified proteins were isolated (Fig. 1C) . The 30-kD protein could not be recovered after elution and thus may represent a protein with only minor CML modifications.
Recently, researchers have shown that CML-modified proteins recognize RAGE (42) . The primary sequence of human RAGE consists of 3 Ig domains followed by a hydrophobic transmembrane region and a 43-residue cytosolic domain at the COOH-terminal (36) . The first Ig domain belongs to the subfamily of variable Ig domains, Ig(v), whereas the second and third are of the constant type, Ig(c). For many extracellular regions of the immunoglobulin superfamily (IgSF), the Ig domain that is located furthest from the membrane and thus closest to a potential ligand is Ig(v). Furthermore, Ig(v) domains are often found to be necessary and sufficient for ligand binding of the extracellular domain of IgSF cell-surface receptors (43, 44) . Therefore, we overexpressed the NH 2 -terminal Ig(v) domain of human RAGE. The addition of this recombinant peptide derived from the IgG-like RAGE domain (soluble RAGE [sRAGE]) as a decoy reduced AGE-RAGE interaction and erythrocyte-derived CML-containing protein-dependent ET-1 induction (Fig. 1D) . Therefore, ET-1 induction by CML-containing erythrocyte-derived protein isolated from patients with poor glycemic control is in part dependent on RAGE. AGEs are able to induce ET-1 in vitro. Elevated ET-1 has been observed in diabetic patients and in complications associated with elevated levels of AGEs (12, 45) , oxidative stress (24) , and increased NF-B binding activity (25) . AGEs prepared in vitro by incubating BSA with 200 mmol/l glucose at 37°C for 4-8 weeks resulted in 10-36% lysine modification. Incubation of BAECs with AGE albumin resulted in a RAGEdependent ET-1 induction because antisense RAGE but not sense RAGE oligonucleotides blocked ET-1 induction in nuclear run-on assays ( Fig. 2A) . Thus, both sRAGE as a decoy and blocking RAGE expression (38) -1-specific primer (top, arrow) and actin-specific primer (bottom, arrow), respectively. 
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The dose-response curve has its half-maximum in the range of the dissociation constant of the AGE-RAGE interaction (17) . The time course showed a rapid increase in ET-1 mRNA synthesis already present at 30 min. This fast induction of mRNA synthesis is comparable with other AGE-RAGE-controlled genes that are controlled by the redoxsensitive transcription factor NF-B. Neither normal albumin nor heat-inactivated AGE albumin had an effect on EC biological functions (data not shown).
Participation of the transcription factor NF-B in AGEmediated ET-1 induction.
BAECs were incubated with 10 µmol/l pDTC. As shown in Fig. 4 , pDTC reduces ET-1 induction, which suggests that AGE-mediated NF-B activation is involved in ET-1 induction (46) . Consistently, transient transfection of BAECs with plasmids overexpressing I-B␣ leads to a partial inhibition of AGE-mediated ET-1 mRNA induction (Fig. 5) . These data suggest that AGE-mediated ET-1 induction is controlled by NF-B. Therefore, transient transfection of BAECs with plasmids overexpressing NF-B p50 and p65 was performed. Induction of ET-1 mRNA through NF-B p50/p65 can be seen in Northern blot analysis. Overexpression of pCAT served as a control (Fig. 6) . Thus, pDTC and overexpression of I-B␣ reduce AGE albumin-mediated ET-1 transcription, whereas overexpression of NF-B induces it, which is consistent with the hypothesis that AGE-
RAGE-dependent ET-1 induction is controlled by NF-B.
Sequence analysis of the EMBL/GenBank database using the Heidelberg Unix Sequence Analysis Resources revealed a potential binding site for members of the NF-B family at position -2,090 bp (Fig. 7) . The EMSA demonstrated AGEinducible binding of protein complexes to this potential binding site. These protein complexes were characterized as NF-B-like proteins through blocking of binding with a 160-fold molar excess of cold consensus NF-B oligonucleotides (Fig. 8) . The functional activity of this NF-B site was demonstrated using chimeric constructs containing the 5Ј (Fig. 10) . Transfection experiments with increasing concentrations of NF-B p50 showed a maximum of promoter activity at a concentration of 1.0 µg p50 DNA, whereas higher concentrations reduced the promoter activity again (Fig. 11) . This finding agrees with data from other groups showing that p50 homodimers have an inhibitory effect on NF-B-dependent gene transcription (47) . nephropathy (14, 15, 22, 23) . In these patients, increased oxidative stress, increased activation of NF-B, elevated levels of ET-1 antigen, and elevated ET-1 gene expression in the glomeruli have been described (23, 25, 45, 48) . Therefore, we investigated whether a link exists among hyperglycemiadependent AGE formation, oxidative stress-dependent NF-B activation, and induction of ET-1 transcription. Clinical studies implicate an association of diabetic complications with increased ET-1 (45, 49) and activation of NF-B (22, 25) . However, NF-B-dependent ET-1 regulation has not yet been described. Structural analysis of the ET-1 promoter revealed a putative NF-B binding site between -2,090 and -2,081 bp. This site is functionally active, as indicated by 1) inhibition of AGE-mediated ET-1 induction through the antioxidant pDTC (Fig. 4) , 2) decreased ET-1 transcription after I-B␣ overexpression (Fig. 5), 3) increased ET-1 transcription after NF-B p50 and p65 overexpression (Fig. 6 ), and 4) promoter studies (Figs. 8-10 ). Thus, ET-1 belongs to the group of the AGE-, RAGE-, and NF-B-regulated genes such as tissue factor and vascular cell adhesion molecule (38,50-52). Consistent with these observations are previous reports describing NF-B-inducing agents as potent stimuli of ET-1 production (3-6,53). The AGE-RAGE-mediated NF-B activation and subsequent NF-B-dependent ET-1 gene expression show a characteristic time course. Consistent with rapid protein synthesis, independent NF-B activation is the rapid AGE-RAGE-mediated induction of ET-1 transcription. The very long-lasting increase in the rate of ET-1 transcription is unusual and is much longer than that seen with stimuli-like cytokines, thrombin, or Ca 2+ ionophores (3, 5, 54) . Thus, AGE-RAGE-dependent ET-1 induction is characterized by its long-lasting time course. Inhibition of NF-B prevented ET-1 induction, even at later time points, and this is consistent with preliminary reports describing an AGE-RAGE-dependent sustained NF-B activation (55) . This finding may explain the high abundance of ET-1 mRNA observed in atherosclerotic tissue. If ET-1 induction is only a short event, as suggested by in vitro experiments using cytokines, thrombin, or oxidized LDL (3-6,53), then only a few cells would be expected to be positive in vivo, whereas others are in a downregulated state. However, the high abundance of ET-1 mRNA in atherosclerotic tissue and the ET-1 positivity of almost all ECs in vivo (56) are more consistent with a perpetuated time course, as observed after AGE-RAGE interaction. The importance of AGE-RAGE interaction has been shown in 2 ways. First, an antisense oligonucleotide previously shown to downregulate RAGE and RAGE-dependent NF-B activation reduced ET-1 induction. Second, a peptide spanning the NH 2 interact with CML proteins in functional assays (A.B., M.S., P.P.N., unpublished data). Because the CML-containing proteins were isolated from an erythrocyte lysate of diabetic patients, we assume that the proteins used are not exclusively CML modified but contain other AGE modifications as well. This indicates that not only CML-modified proteins use the RAGE region AA21-132 as their binding site.
The fact that in vitro-generated AGEs and hyperglycemiadependent AGE-modified proteins isolated from an anti-CML column are able to induce ET-1 indicates that the AGEmediated ET-1 induction is not an in vitro artifact. This conclusion is supported by a recent study showing that sRAGE protects hyperlipidemic diabetic mice from macrovascular atherosclerosis (19) .
The data herein point to AGE-modified erythrocytes as potential sources of RAGE ligands, supporting a previous study that demonstrated binding of AGEs on the surface of erythrocytes to RAGE, which results in oxidative stress (21) . This concept is expanded by our study showing that this interaction results at least in vitro in NF-B-dependent ET-1 induction. DIABETES 
